|
The document details a toxicity test of perfluorooctylsulfonate (PFOS) on the aquatic plant species Selenastrum capricornutum, conducted by AScI Corporation, which involved a 96-hour exposure to a mixture of the test substance in water, with nominal concentrations reported and various environmental parameters monitored.
|
— |
AR226-0536
|
yqgawgo8k2KZZaMMEVLVGoJE |
13 |
|
The document details a toxicity study of perfluorooctylsulfonate (PFOS) conducted on the aquatic plant species Selenastrum capricornutum, using a test sample produced by 3M, which was assessed for its impact on algal growth over a 96-hour exposure period.
|
— |
AR226-0537
|
wqxnVgGyD9k29yXK9KOvZOeMQ |
14 |
|
This document is an assay revalidation report prepared by Northwest Bioanalytical for 3M, detailing the quantitative determination of PFOS and related compounds in human serum using LC/MS/MS, conducted under Good Laboratory Practice guidelines.
|
— |
AR226-1209
|
MJaNvDEVq5wRGnVpwErk6Z0MM |
103 |
|
This is a TSCA NCIC Notification Form related to confidential business information under the Toxic Substances Control Act, with no analytical content retained in the OCR.
|
— |
AR226-1214
|
rp9XpeQmzGj05qGZ7dd9aMZKv |
1 |
|
This document is an assay validation report from Northwest Bioanalytical for the quantitative determination of PFOS and its metabolites in human serum, prepared for 3M Environmental Technology and Services, confirming adherence to Good Laboratory Practice guidelines.
|
— |
AR226-1210
|
qmomvgnZZ2QDKZKMEVjdEN2Rn |
135 |
|
The document is a study report from Northwest Bioanalytical detailing the quantitative determination of PFOS and related compounds in human serum using LC/MS/MS, prepared for the 3M Company's Corporate Occupational Medicine department.
|
— |
AR226-1213
|
X7aDErzB8YRpOGMrvRO5J7kyG |
76 |
|
This document is a sample analysis report from Northwest Bioanalytical detailing the quantitative determination of PFOS and related compounds in human serum, prepared for 3M Company, and conducted under FDA Good Laboratory Practice guidelines.
|
— |
AR226-1211
|
mmgx76Qk2ao7389v4pmGwX6Y0 |
124 |
|
This document is a sample analysis report from Northwest Bioanalytical for 3M Company, detailing the quantitative determination of PFOS and related compounds in human serum using LC/MS/MS under study protocol EPI-0013.
|
— |
AR226-1212
|
K6d4q62XBoXmvQ4qLzG9rVb2w |
136 |
|
The document presents quarterly analytical results for perfluorononanoic acid (PFNA) from Washington Works, detailing relative percent recovery (RPR) values for quality control samples during sample preparation.
|
— |
AR226-1678
|
ppaRp09opMXB4M52zZ6p2mXdd |
2 |
|
Unreadable document.
|
— |
AR226-1687
|
oemO7g5NbXELMpwzxQkXa195o |
1 |
|
The document is an analytical report from Exygen Research detailing the characterization of water samples for perfluorooctanoic acid (PFOA) collected by E. Roberts Alley and Associates, using liquid chromatography/tandem mass spectrometry (LC/MS/MS) methods.
|
— |
AR226-1703
|
DDGm6JVwV5LGg82XR6491LxVN |
48 |
|
This analytical report from Exygen Research details the fluorochemical characterization of water samples received from Daikin America, specifically analyzing for perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) using liquid chromatography/tandem mass spectrometry (LC/MS/MS).
|
— |
AR226-1704
|
X7Qnz47bjY9a5v456xMm44GEy |
54 |
|
This analytical report from Exygen Research details the fluorochemical characterization of water samples from Daikin America, Inc., specifically focusing on the detection of Perfluoroctanoic Acid (PFOA) using liquid chromatography/tandem mass spectrometry (LC/MS/MS).
|
— |
AR226-1708
|
V1EVxGQLY2y3mqokwnbY060o |
147 |
|
The document discusses a report by 3M regarding an oral study on perfluoroalkane carboxylic acids and their ammonium carboxylates, indicating teratogenic effects in pregnant rats, and submits this information to the EPA under Section 8(e) of the Toxic Substances Control Act, while noting no observed human health problems related to fluorochemical exposure.
|
— |
AR226-1373
|
mmqZjNNDRZqLQenK3nj52D8Yk |
13 |
|
A study by 3-M reported to the EPA found that ammonium perfluorooctanoate (C-8 compound) caused eye scarring in rat fetuses following maternal exposure, raising concerns about potential reproductive effects among female employees at the Parkersburg facility.
|
— |
AR226-1375
|
byLBZ5YzyZ6wBJR1bgQYegmQo |
2 |
|
The document outlines a timeline of actions taken by 3M and Du Pont in response to embryotoxic effects observed in preliminary animal studies involving C-8 (PFOA), including employee reassignments and blood sampling procedures initiated in March and April 1981.
|
— |
AR226-1374
|
NG2e0ZKLdvDrDY1ZRnRKMoN8D |
71 |
|
The document is a notification from 3M to the EPA regarding perfluoroalkane carboxylic acids and corresponding ammonium carboxylates under Section 8(e) of the Toxic Substances Control Act, indicating that certain parts of the notice are considered trade secrets.
|
— |
AR226-1376
|
yrVLm5X2DYoLwEo6dLj0Lk21D |
15 |
|
The document discusses a Rangefinder Study conducted by 3M on ammonium perfluorooctanoate (C-8) in pregnant rats, confirming that observed fetal eye changes were due to C-8, and outlines plans for a subsequent oral teratology study to determine a no-effect level, with a top dose of 150 mg/kg/day.
|
— |
AR226-1377
|
m83agJ53E5a82zN95mEv3b5b |
3 |
|
The document discusses preliminary results from a study by 3M indicating that the fluorosurfactant C-3 (ammonium perfluorooctanoate, also known as C-8) caused birth defects in rats, prompting further investigation into its potential effects and relevance to employee exposure at DuPont's Teflon Polymers Division.
|
— |
AR226-1378
|
2J6VBZrMDee47Bx08nkxMQD1p |
8 |
|
The document discusses a proposed epidemiology study on reproductive effects related to workplace exposure to C-8 (a perfluorinated compound), highlighting the need for comprehensive data collection involving employees and suggesting a delay in initiating the study until results from Du Pont's ongoing pregnancy outcome study are available.
|
— |
AR226-1379
|
Gm634oo60QD9xbQJBYEvZR6Nn |
2 |
|
The document discusses a request for non-objection to delay an epidemiology study on pregnancy outcomes among employees exposed to C-8 (PFOA), indicating that new information suggests the need for the study, with ongoing evaluations by the Medical Division.
|
— |
AR226-1380
|
rpm5z0ddY8Oa6v7zjRQ2YLQpq |
2 |
|
The document is a research proposal from the Employee Relations Department Medical Division Epidemiology Section, dated April 13, 1981, aimed at investigating whether pregnancy outcomes among female Washington Works employees and their wives are causally related to occupational exposure to C-8 (PFOA), with background information on previous toxicological studies and findings of eye lens abnormalities in fetuses from a related study.
|
— |
AR226-1381
|
N2ogGdRG1bO8bdbXrr8kGgVpR |
18 |
|
The document outlines a blood sampling program for employees at Washington Works to assess levels of C-8 (PFOA) in order to provide health information and counseling for pregnant and non-pregnant females, as well as to confirm exposure levels among males and support epidemiological studies.
|
— |
AR226-1382
|
2JJ5d4j673MwDVvaDB6O6ngEb |
4 |
|
The document outlines a proposed study to investigate whether pregnancy outcomes among female employees and their spouses at the Washington Works plant are causally related to occupational exposure to perfluorooctanoic acid (C-8), dimethylformamide (DMF), or hydrofluoroalkane (HFA), but the study is currently on hold due to objections regarding the questionnaire used.
|
— |
AR226-1383
|
dYnR4ENbLDDQ2Q5w2QqyNLvVq |
2 |
|
This document appears to be a word processing work form intended for the Employee Relations Department, detailing instructions for typing and corrections, but contains no analytical content related to PFOA/PFOS.
|
— |
AR226-1384
|
NEpgR8ByKym7ZrMJbz7rexEQg |
9 |
|
The document discusses ongoing blood level testing for C-8 (perfluorooctanoic acid, PFOA) among exposed employees and controls, reporting non-detectable levels in controls and mentioning an animal study to determine a "no-effect" level in rats, while maintaining a standard of 0.0-0.4 ppm total organic fluorides for workplace safety.
|
— |
AR226-1385
|
EdOMz45zaR7DqgJm8x56QeJxL |
2 |
|
The document reports the analysis of 48 blood samples for perfluorooctanoate (PFOA) conducted by E. I. du Pont de Nemours and Company, detailing the method used, precision, and quantitation limits of the results.
|
— |
AR226-1386
|
ba1D4NOKY2ekjnY73xv11QYzo |
4 |
|
This document reports the analysis of 14 blood samples for perfluorooctanoate (PFOA) conducted by the DuPont laboratory, detailing the concentrations found and the methods used for quantification.
|
— |
AR226-1387
|
wqGv4wgXJpvND4w7r3k7LNMy4 |
3 |
|
The document reports the analysis of 21 blood samples for perfluorooctanoate (PFOA) conducted by S. S. Stafford, detailing the results, methods used, and precision of the measurements.
|
— |
AR226-1389
|
G5x5EXeEoYxxZpww2KK6eMr37 |
3 |
|
This document from E. I. du Pont de Nemours & Company discusses the status of the C-8 program, which involves further animal testing and blood sampling related to the teratogenic potential of C-8 (PFOA), following findings from 3M, and includes updates on risk assessments and studies being conducted at Haskell Laboratory.
|
— |
AR226-1388
|
KJrO8DdzqJQoYjqnzqj5KbBZX |
11 |
|
The document outlines a proposed blood sampling program by E.I. du Pont de Nemours & Company to assess employee exposure to C-8 (perfluorooctanoic acid, PFOA) at Mitsui Fluorochemicals Co. Ltd.'s Shimizu Works, aiming to compare exposure levels with those at Washington Works.
|
— |
AR226-1390
|
b5BbZnk24GBDx2n3R0E9M6kEk |
6 |
|
The document details the analysis of blood samples for perfluorooctanoate (PFOA) conducted by E. I. du Pont de Nemours and Company, reporting various concentrations of PFOA in the samples analyzed using gas chromatography.
|
— |
AR226-1391
|
93XoV0QoqxMRnq5Oa6ErdVy8V |
3 |
|
The document discusses the status of C-8 (ammonium perfluorooctanoate) and reports that further studies by 3M indicate that previously observed eye defects in unborn rats were likely due to preparation techniques rather than exposure to C-8, leading to a potential reassessment of employee exposure restrictions.
|
— |
AR226-1392
|
VJw71DepQEg1LrrkbE70aMQvZ |
3 |
|
This document is a communication from E.I. du Pont de Nemours & Company regarding inquiries from individuals concerned about potential health effects related to C-8 (PFOA), specifically questions about birth defects and safe blood levels for children.
|
— |
AR226-1393
|
zz1ErRD8ZXOwrOb4DYD8rOn6 |
2 |
|
The document details a meeting between E. I. du Pont de Nemours & Company and 3M regarding C-8 (perfluorooctanoic acid, PFOA), discussing negative teratology studies in rats and rabbits, employee blood organofluorine levels, and plans to inform employees about the study results.
|
— |
AR226-1394
|
jyX2bjLOMxaNznvgoqj16kabR |
3 |
|
The document discusses the results of animal studies conducted by DuPont and 3M on C-8 (perfluorooctanoic acid), concluding that it does not cause teratogenic effects, which allows female employees of childbearing capability to return to areas with potential exposure to C-8.
|
— |
AR226-1395
|
2qmJ87bw45ve2247GjxGjeRYr |
2 |
|
The document is a memo reporting to the EPA on teratogenic studies of ammonium perfluorooctanoate (FC-143) conducted by 3M, indicating that subsequent findings showed no significant teratogenic effects, despite earlier notifications suggesting potential eye defects in rat fetuses.
|
— |
AR226-1396
|
bO4O96y9m2pY98OZQpgGJ3BKy |
3 |
|
The document reports on a study conducted by E.I. du Pont de Nemours & Company regarding the placental transfer of ^14C-perfluorooctanoate (C-8) in albino rats, demonstrating that the compound does transfer across the placenta, with measured maternal and fetal blood levels at various time points post-dosing.
|
— |
AR226-1397
|
byENxby4k492n7mbk7RNV68n1 |
2 |
|
The document discusses the evaluation of employee exposure to C-8 (perfluorooctanoic acid, PFOA) at the Washington Works facility by E. I. du Pont de Nemours & Company, indicating that while current exposure levels are low and no chronic health effects have been established, there is a recommendation to implement measures to further reduce exposure due to concerns about long-term health effects
|
— |
AR226-1398
|
aB96dx0VQRJGzJG57Ve4kwpKY |
3 |
|
This document summarizes the sampling procedures and results for C-8 (perfluorooctanoic acid, PFOA) concentration in drinking water collected from various locations downstream of a plant, detailing the challenges faced during analysis and the eventual decision to send samples for external testing due to analytical issues.
|
— |
AR226-1399
|
g2vvON580QYaLrJ1yYk6OZZOJ |
7 |
|
This interoffice memorandum from DuPont discusses the analytical results of five water samples for perfluorooctanoate (C8), indicating a detected concentration of 1.9 ppb, which is higher than previous measurements but not significantly different due to proximity to the detection limit.
|
— |
AR226-1400
|
G6BYgDrzD1352oXxdKKyd0J2V |
5 |
|
This document is an analytical report from Exygen Research detailing the characterization of soil samples for perfluorooctanoic acid (PFOA) collected by E. Robert Alley and Associates, using liquid chromatography/tandem mass spectrometry (LC/MS/MS) methods that have been adapted for soil analysis.
|
— |
AR226-1705
|
YEdxbMzdayOOpLbyaMXkrqOV |
202 |
|
This analytical report from Exygen Research details the fluorochemical characterization of soil samples for perfluorooctane sulfonate (PFOS) using liquid chromatography/tandem mass spectrometry (LC/MS/MS), indicating that while methods were adapted for soil analysis, full validation has not yet been completed.
|
— |
AR226-1706
|
QXMqvVMMkowwxZnydbZjv2MV6 |
207 |
|
The document is a memo from E. I. du Pont de Nemours & Company requesting the establishment of acceptable levels for ammonium perfluorooctanoate (C-8) in blood and community drinking water.
|
— |
AR226-1401
|
RJy9aBak9dQg59V6mqYQ7YV87 |
2 |
|
The document discusses acceptable exposure levels for ammonium perfluorooctanoate (C-8), suggesting a blood level of 0.5 ppm for workers and a drinking water concentration limit of 5 ppb based on exposure assessments and toxicity data.
|
— |
AR226-1402
|
rpwx03oyw21V74Nk8ZOVBE4LJ |
3 |
|
The memorandum requests the establishment of a CEG (Concentration Exposure Guideline) for Ammonium Perfluorooctanoate (PFOA) in drinking water, based on health effects observed in residents near a Washington Works Plant, and seeks timely action to inform future decisions.
|
— |
AR226-1403
|
NGEE48z13GBx8vpR4YLoLg5Gw |
2 |
|
The document outlines changes to the Acceptable Exposure Limits (AEL) list for various chemicals, including ammonium perfluorooctanoate (C-8), with a specified limit of 1 µg/L, as discussed in a June 1991 meeting of the Du Pont AEL Committee.
|
— |
AR226-1404
|
ooOxxN6BR65Mv2yXRxDg6K3o |
10 |
|
The document details a meeting regarding the proposed C-8 (PFOA) sampling program at the Washington Works site, highlighting inconsistent levels of C-8 detected in various wells, with higher concentrations near the old supernate ponds, and discusses the development of a new detection technique for C-8 down to 0.1 ppb.
|
— |
AR226-1405
|
zdNrrEzOQNLbOy9RGKvO8RMk7 |
13 |
|
The document contains E. I. du Pont de Nemours and Company's responses to the plaintiffs' third set of requests for admissions in a civil action regarding PFOA-related claims in West Virginia, asserting general objections and clarifying that any admissions made are for the purpose of the current case only.
|
— |
AR226-1406
|
MMrgB2dDq06MNGEmG2KNgXpaL |
38 |
|
This document contains E. I. Du Pont de Nemours and Company's responses to Plaintiffs' second set of requests for admissions in a civil action regarding PFOA-related claims, outlining general objections and the context of the admissions.
|
— |
AR226-1407
|
YbRymRZ6xM75NXgr9jypB9vy |
68 |
|
The document provides water quality data from various locations near Parkersburg, West Virginia, indicating levels of PFOA (C-8) detected in water samples collected on March 15, 1984, and June 4, 1984, with specific measurements noted for upstream and downstream sites.
|
— |
AR226-1409
|
kay1zZaa0n96mG34eYJ4baXrD |
1 |
|
This document appears to be a sampling log or data sheet listing various water sampling locations and dates, with some analytical results indicating the presence of C-8, likely related to PFOA/PFOS analysis.
|
— |
AR226-1411
|
EmmJa9DeRzzvJwqLJbnwd2EEn |
1 |
|
This is a laboratory report detailing water sampling results with various measurements for contaminants, including PFOA/PFOS, from multiple buildings, although the specific analytical content is not fully retained in the OCR.
|
— |
AR226-1412
|
1gnkNbrov72J7eRVaYK68o0aj |
1 |
|
Unreadable document.
|
— |
AR226-1414
|
wEwOZz6gvzKX1mMDRdxVER13 |
1 |
|
This analytical report from Exygen Research, requested by Daikin America, details the characterization of a surface water sample for perfluorooctanoic acid (PFOA) using liquid chromatography/tandem mass spectrometry (LC/MS/MS).
|
— |
AR226-1710
|
mBRMeO8ydQDe4Ob6ob12Z7KXQ |
44 |
|
The document is an analytical report from Exygen Research for Daikin America, detailing the characterization of surface water and sediment samples for perfluorooctanoic acid (PFOA) using liquid chromatography/tandem mass spectrometry (LC/MS/MS).
|
— |
AR226-1709
|
G5xNJ7JKQ70Er3G8nmexr85jY |
148 |
|
The document is an analytical report from Exygen Research detailing the fluorochemical characterization of water and sludge samples for perfluorooctanoic acid (PFOA) received from Daikin America, Inc., using liquid chromatography/tandem mass spectrometry (LC/MS/MS).
|
— |
AR226-1711
|
re7Z31reyqg4N14ewxxEyJbNa |
99 |
|
This is a TSCA NCIC Notification Form related to confidential business information, with no analytical content retained in the OCR.
|
— |
AR226-1434
|
r69KwwOdy6kq6qabenR2ZEjv0 |
1 |
|
Unreadable document.
|
— |
AR226-1435
|
XOLqk3jvp3Yg67kdJdR0vZaeR |
1 |
|
This is a TSCA NCIC Notification Form regarding confidential business information (CBI) related to a document claimed under Section 14 of the Toxic Substances Control Act.
|
— |
AR226-1436
|
qd4bLj02rEeeL51qgamyjbw7k |
1 |
|
This is a TSCA NCIC Notification Form for confidential business information related to a document under the Toxic Substances Control Act, with details on accessing the information for those with TSCA CBI clearance.
|
— |
AR226-1437
|
jBQKK1gpdoge1Gm5x9Y2m9gjZ |
1 |
|
This is a TSCA NCIC Notification Form for confidential business information related to a document claimed under Section 14 of the Toxic Substances Control Act.
|
— |
AR226-1438
|
pemXm7q7bLRy01Xo9L8Vk4q5a |
1 |
|
The document discusses the analysis of PFOA in various commercial products, including textiles and upholstery, and provides sales data and application information for these products in the U.S. as of 2002.
|
— |
AR226-1439
|
qmpvd5wzNBLgLzxr66V8EvMeG |
3 |
|
This document appears to be a laboratory report discussing the effects of a chemical on rat liver and kidney morphology and weight changes, with specific dose levels noted and observations on organ response to treatment.
|
— |
AR226-1442
|
OEae4gR4n5vGg7j39LyX7MYMv |
52 |
|
The document reports on a study investigating the effects of ammonium 3,6-aioxa-2,5-ditrifluoroethylundecafluorononanoate (AHT) and other fluorocarbon dispersing agents on liver enlargement and function in rats and dogs, highlighting significant liver enlargement observed after a single sublethal dose of AHT.
|
— |
AR226-1443
|
3Jm2EgDKQMdXeJR1DenmYwbJ6 |
19 |
|
The document discusses the disposal of solid waste containing perfluorinated compounds (C-8) from the Teflon plant, concluding that baking the waste at 175°C for 5 hours reduces the toxic dispersing agent levels to below 2 ppm, thus preventing groundwater contamination.
|
— |
AR226-1444
|
jmG0r46OGw3ka6p3v26YB4XVR |
6 |
|
The document outlines the disposal procedures for "Teflon" scrap containing C-8 or C-9 dispersing agents, specifying that wet scrap must be kept on-site for future sea disposal, while dry and certain other wet scraps can be moved to the plant landfill.
|
— |
AR226-1445
|
Yj8yV8vjyoj2nqjrzjjqwb5pD |
2 |
|
The document is a request from W. E. Hilton of DuPont's Fluorocarbons Division for toxicological information regarding ammonium perfluorooctanoate (C-8 APFC), highlighting its known toxicity and seeking studies on its chronic effects and necessary protective equipment.
|
— |
AR226-1446
|
7MoJ2nQ2Z1xKvKVD6z4x0w9ga |
7 |
|
This is a letter from W.E. Hilton of the Fluorocarbons Division discussing toxicological information on CgAPFC and suggesting various tests to evaluate its toxicity and effects on liver enlargement in rats.
|
— |
AR226-1447
|
EdyyN9kZEQRb1z6GG1Eo7vDVR |
5 |
|
The document reports a study evaluating the incidence of myocardial infarction among male employees at the Washington Works Plant from 1956 to 1973, revealing 61 observed cases and comparing them to expected rates based on Du Pont Company statistics.
|
— |
AR226-1448
|
Ra4499O9Z9Bw3qg0OxMyZqNba |
10 |
|
The document outlines a medical program initiated by Du Pont to assess potential occupational hazards from exposure to certain fluorochemicals, specifically focusing on workers handling Telomer A-derived fluorochemicals, and includes plans for blood analyses and additional toxicity tests on various fluorosurfactants.
|
— |
AR226-1450
|
jyoyyxayLmp5qMO7BZxbya4by |
4 |
|
The document discusses a paper by Guy and Taves that examines the prevalence and characterization of organic fluorocompounds, specifically focusing on a non-exchangeable form of fluoride found in human plasma, which may have implications for understanding environmental sources of perfluorinated fatty acids.
|
— |
AR226-1449
|
Z4G1b425Y62G5jqo4yqQZLKjV |
20 |
|
The document is an analytical report from Exygen Research detailing the characterization of water samples for perfluorooctanoic acid (PFOA) received from Daikin America, using liquid chromatography/tandem mass spectrometry (LC/MS/MS) methods.
|
— |
AR226-1712
|
44D9Za9p9oD96xxrzDY581851 |
65 |
|
This analytical report from Exygen Research details the characterization of water samples for perfluorooctanoic acid (PFOA) received from Daikin America, utilizing liquid chromatography/tandem mass spectrometry (LC/MS/MS) methods.
|
— |
AR226-1713
|
RjvVLkYkJkmyy97qKayXOweO7 |
48 |
|
The document outlines a communication schedule for informing Chambers Works employees about the presence of organic fluorine substances, including PFOA, in human blood plasma, with a specific announcement planned for June 27, 1978.
|
— |
AR226-1451
|
ka9vr37m07K2qqwVD0xVX6ewq |
11 |
|
The document discusses recommendations for a medical surveillance program for employees potentially exposed to C-8 (a perfluorinated compound) at the Washington Works facility of DuPont, emphasizing the need for regular periodic examinations.
|
— |
AR226-1452
|
YGO7LXg32von9dEj0LYmGwXLO |
6 |
|
The document is a medical review of eleven operators and eighteen laboratorians with long-term exposure to C-8 (PFOA), concluding that while some borderline elevations in liver function tests were observed, no unusual health problems were identified, and the findings are not statistically valid.
|
— |
AR226-1453
|
OE431Q9drw2Q97BONrke5aYEv |
3 |
|
The document discusses a fluorosurfactant study conducted by E.I. du Pont de Nemours and Company, indicating that while no significant adverse health effects were reported, there may be concerns regarding liver function that require further analysis and data presentation.
|
— |
AR226-1454
|
yKkDVk93obzOEBm6LZLoMQY2 |
3 |
|
The document is a correspondence from 3M to Dr. Blaine McKusic at E.I. DuPont de Nemours & Co., sending reports on toxicity studies of the fluorochemical FC-143, which is related to perfluorinated compounds.
|
— |
AR226-1455
|
M4vYX3JGK7KBXYE0e8xzXQQZM |
2 |
|
This is a letterhead cover page from an unspecified organization, with no analytical content retained in the OCR.
|
— |
AR226-1456
|
4vkXZz5ZMvBMQL902VQB86w81 |
2 |
|
The document discusses a statistical analysis of health data from employees exposed to PFOA at DuPont's Chambers Works, revealing significantly higher incidences of allergic, endocrine, metabolic, and mental disorders in the exposed group compared to the control group, along with abnormal liver function tests.
|
— |
AR226-1457
|
e7Qv7O2gawVLxk9ypkJXgrq29 |
3 |
|
The document discusses findings from 3M regarding organic fluorocarbons, including PFOA, in the blood of employees exposed to long-chain perfluoro surface-active materials, revealing blood levels ranging from 1 to 71 ppm, and outlines Du Pont's actions to assess and control exposure among its employees.
|
— |
AR226-1458
|
2J6g07652Yx8wrLypwD0a3R25 |
16 |
|
The document details a meeting held on July 18, 1979, involving E. I. du Pont de Nemours & Company personnel to review preliminary data on organic fluorine levels in blood related to C-8 (PFOA) exposure, with plans for further blood sampling to verify exposure sources and a subsequent meeting with 3M Company to discuss additional data.
|
— |
AR226-1459
|
MJ5E9ENqzZw4g7Mden9OQ9mNV |
7 |
|
The document discusses findings related to organic fluorocompounds, specifically perfluorooctanoic acid (PFOA), in human blood, noting elevated levels in employees exposed to long-chain perfluoro surfactants from 3M Company, while indicating no adverse health effects and a slow decay rate of fluorine levels in the body.
|
— |
AR226-1460
|
Q823qjJokxmOaxwnj1a34wqE |
4 |
|
The document discusses a meeting held on July 23, 1979, regarding the review of fluorine blood levels in employees exposed to ammonium perfluorooctanoate (3M's FC-143), concluding that there was no substantial risk or adverse health effects, and thus no reporting under TSCA Section 8(e) was required.
|
— |
AR226-1461
|
rB6BgYqZZGdmqEqK0yNDY33GJ |
2 |
|
The document is a status report from DuPont regarding a liver function survey and coronary heart disease mortality study for workers exposed to C-8 (PFOA), indicating preliminary findings of higher liver function test results and myocardial infarction cases among these workers compared to the general plant population, prompting further investigation and data collection.
|
— |
AR226-1462
|
gaRevzdnaXjwMGY7key31vB4e |
5 |
|
The document from E. I. du Pont de Nemours & Company discusses the results of blood analyses for organic fluorides, specifically indicating that previous results were incorrect due to the failure to subtract inorganic fluoride from total nonvolatile fluoride, with a plan to update the findings as more data becomes available.
|
— |
AR226-1463
|
Qgj15rwMEMmwyZLV4L0mOK9mk |
18 |
|
The document reports on blood analyses for organic fluoride levels in workers, indicating low concentrations of perfluorinated compounds (average 0.35 ppm for Monomer Operators and 0.56 ppm for laboratorians), which do not warrant further sampling.
|
— |
AR226-1464
|
V3oE0z4K59jzMy46qOEKMpJ5q |
2 |
|
The document discusses a liver enzyme study of workers exposed to C-8 (PFOA) at the Parkersburg plant, concluding that while there are elevated enzyme levels in certain groups, there is no conclusive evidence of an occupationally related health problem, but further follow-up is recommended due to inconsistencies in laboratory results.
|
— |
AR226-1465
|
jmMVRm6ye7n7XrzpmDgEKd8ON |
3 |
|
This document appears to be a data report from February 1980 detailing blood analysis results for FC-143 exposure at a Toledo site, including concentrations of total and organic fluorine in parts per million.
|
— |
AR226-1466
|
85kba3gOVwvjNLeDObk4nwqVB |
2 |
|
The document discusses blood tests conducted on employees exposed to FC-143, a fluorosurfactant produced by 3M, revealing significant levels of organic fluorine in their blood compared to general background levels, although no adverse health effects were detected.
|
— |
AR226-1467
|
ppqgL5gJXrxzKY6O8mNokMVMw |
3 |
|
The document summarizes the levels of organic fluorides, including PFOA and PFOS, found in blood samples from various job groups at different production facilities, indicating a range of concentrations and average levels among employees.
|
— |
AR226-1468
|
GmY7EgmrpLMM7qqpqaO20ZJnr |
2 |
|
The document is a memo from Vanna A. Brewster, M.D., expressing concerns about the continuation of liver tests for employees potentially exposed to C-8 (PFOA) and recommending that the study should proceed despite the lack of conclusive evidence of health problems.
|
— |
AR226-1469
|
3Nro1rNM0D6NmdQzZqEd978zn |
2 |
|
The document discusses the results of blood analyses for perfluorinated compounds, specifically detailing comparisons between August 1979 and August 1980 samples analyzed by the C-8/GC method, indicating a significant increase in values for certain individuals and the need for further explanation of these results.
|
— |
AR226-1471
|
wqBe9NEbdL03Vw8R02j3mJ6M6 |
24 |
|
The document outlines a communications meeting regarding the toxicity and safety measures related to C-8 (PFOA) used in TFE and FEP manufacturing, highlighting its oral and inhalation toxicity, initial blood test results, a provisional acceptable exposure limit (AEL) of 0.55 ppb, and proposed equipment improvements to reduce exposure.
|
— |
AR226-1470
|
ExzQOvD16vLDZjYaDkmLg5XOb |
53 |
|
This is a draft report prepared by Mark D. Sprenger, Ph.D., and Michael T. Horne, Ph.D., for the Environmental Response Team and U.S. Fish & Wildlife Service, detailing the technical approach and preliminary risk screening for the Dry Run Creek site in Wood County, West Virginia, from November 1997.
|
— |
AR226-1474
|
XOGRBzKye67d0gRbrk1b4LbRx |
66 |
|
The interoffice memorandum discusses the results of water samples taken at the Dry Run Landfill, indicating the presence of C8 (likely referring to perfluorooctanoic acid, PFOA) in some samples, which raises concerns about potential leaching from Teflon supernate pond sites and suggests the need for additional testing.
|
— |
AR226-1475
|
ymvGJn2rGgoZgX3VQVZ31D5YD |
4 |
|
The document summarizes the history of C-8 (PFOA) disposal and monitoring at the Dry Run Landfill, noting the disposal of 7,100 tons of soil containing approximately 85 ppm of C-8, annual groundwater and surface water monitoring results since 1991, and the disposal of fluoropolymer waste starting in 1996.
|
— |
AR226-1476
|
pp8vdx5mo8mz00OpbvoqBkoJ6 |
2 |
|
This is a letterhead cover page indicating that the document is claimed as confidential business information under TSCA, with no analytical content retained in the OCR.
|
— |
AR226-1479
|
nmDz3XDBZRZoboXR2bbekKYQw |
1 |
|
Unreadable document.
|
— |
AR226-1480
|
evzRJrvrD08bJv8KpvzVeBxrG |
1 |